Campath在恶性血液系统疾病中的应用
摘要
Campath,抗CD52单抗,能特异地针对表达在淋巴细胞和单核细胞表面的CD52抗原,通过相关的免疫机制杀伤靶细胞。目前Campath临床主要用于治疗恶性淋系血液肿瘤、自身免疫性疾病以及移植抗宿主病的防治。本文综述了Campath近年来的在恶性血液系统疾病中治疗现状和进展。
出处
《国际输血及血液学杂志》
CAS
2006年第2期147-149,共3页
International Journal of Blood Transfusion and Hematology
参考文献20
-
1Rowan W, Tite J, Toplly p, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology, 1998, 95(3) :427-436.
-
2Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research,1998, 22(2):185-191.
-
3Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glyeosylphosphatidylinositol-anchored glycoprotein. Immunotechnology, 1995, 1 (3-4) : 175-187.
-
4Wolff D, Steiner B, Stilgenbauer S, et al. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD. Eur J Haematol,2004,72(2) : 145-148.
-
5Gautschi O, Blumenthal N, Streit M, et al. Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H). Eur J Haematol, 2004,72(1):61-63.
-
6Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clinical Oncol, 2005, 23(13):2971-2979.
-
7Galimberti S, Cervetti G, Cecconi N, et al. Quantitative Molecular Evaluation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia: Efficacy of In Vivo Purging by Alemtuzumab (Campath-1H). J Immunother, 2004, 27( 5):389-393.
-
8Dearden CE, Matutes E, Cazin B, et al. High remission rate in Tcell prolymphocytic leukemia with CAMPATH-1H. Blood, 2001,98(6) : 1721-1726.
-
9Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol, 1997,15 (7) : 2667-2672.
-
10Keating MJ,Cazin B, Coutre S, et al. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. J Clin Oncol,2062, 20(1):205-213.
-
1刘蓓,吴晓雄,马健,曹永彬,王志红,徐丽昕,闫蓓,刘周阳.恶性血液系统疾病合并肺部真菌感染30例临床分析[J].感染．炎症．修复,2009,10(3):189-189.
-
2唐文茹.(t5;7)急性早幼粒白血病1例报告[J].甘肃医药,2013,32(11):878-878.
-
303057 FDA专题小组推荐Campath[J].国外药讯,2001(3):31-31.
-
4张曼,苏丽萍,王江涛.自然杀伤细胞在恶性血液系统疾病中应用的研究进展：第56届美国血液学会年会报道[J].白血病．淋巴瘤,2015,24(4):200-202.
-
5金正明,邵景章,李建勇.老年恶性血液系统疾病医院真菌感染分析[J].江苏医药,2000,26(4):309-309.
-
6金正明,邵景章,仇红霞,仇惠英.78例老年恶性血液系统疾病医院感染情况分析[J].苏州医学院学报,2000,20(6):529-531. 被引量：1
-
7麦玉洁,邱录贵.三氧化二砷治疗恶性血液系统疾病的机制[J].国外医学（生理病理科学与临床分册）,2004,24(2):166-169. 被引量：3
-
8景新（摘）.Campath降低MS复发风险但有安全性问题[J].国外药讯,2006(2):38-38.
-
9陈志哲.前言——重视老年恶性血液系统疾病的诊治[J].实用老年医学,2004,18(2):59-59. 被引量：1
-
10潘湘涛,陆晔,王金湖,程旭,李蓉,严敏.淋系血液肿瘤患者BAFF和APRIL表达及意义[J].现代检验医学杂志,2010,25(1):74-76. 被引量：1
